Tegoprazan Could Ease Nonerosive Reflux Disease Symptoms
A new phase 3 trial suggests this treatment may help adults who do not find relief with standard acid-suppressing medications.
Updated on Oct. 22, 2026 in Diabetes
Live Poll
Do you trust new medical treatments to provide better symptom relief than current standard therapies?
A new phase 3 trial shows that the drug tegoprazan significantly reduces symptoms of nonerosive reflux disease compared to a placebo. This development offers a potential new path for patients who do not find relief with standard treatments.
Why it matters
About half of patients with nonerosive reflux disease do not achieve adequate symptom control using standard proton pump inhibitors. This trial suggests a new pharmacological option could eventually help fill that treatment gap.
In a phase 3 trial of 783 adults with nonerosive reflux disease, daily doses of 50 mg or 100 mg of tegoprazan resulted in higher percentages of heartburn-free days compared to a placebo. Researchers noted that the primary efficacy outcomes were met, though further study is needed.
The details
Tegoprazan works as a potassium-competitive acid blocker, a class of medication that inhibits gastric acid secretion by binding to the proton pump in the stomach. In this trial, participants received daily doses or a placebo over a 4-week primary phase, followed by a 16-week extension. Treatment-emergent adverse events were reported in 22.9% to 27% of study participants across all groups, with gastric levels remaining within normal ranges.
Timeline
Differences in symptom relief between the drug and placebo emerged on Day 1.
The initial treatment phase of the phase 3 trial lasted 4 weeks.
Researchers followed participants through a 16-week extension phase ending at week 24.
Gastric levels returned to baseline 2 weeks after participants discontinued the medication.
Health Landscape
For patients with nonerosive reflux disease, proton pump inhibitors currently serve as the standard of care, yet they leave many patients without full symptom relief. This study evaluates how a newer class of acid-blocking drugs compares to that benchmark.
If you struggle with persistent heartburn or regurgitation despite using standard acid-suppressing medication, this new finding is a topic worth discussing with your doctor. They can provide context on available treatments and whether participating in future clinical research may be appropriate.
The takeaway
While this new medication shows promise for symptom control in nonerosive reflux disease, it is not yet a standard treatment option. Always track your symptoms in a journal to discuss specific patterns and frequency with your physician at your next checkup.
Further reading
For more on managing chronic digestive health conditions, visit Diabetes.
Source note: This article includes information reported by Healio.
Live Poll
Do you trust new medical treatments to provide better symptom relief than current standard therapies?
